Professional Documents
Culture Documents
Antibiotic characteristic
-Invitro activity
Empiric Terapy - excelence bone penetration
-good tolerance
Cefazolin
Lazzarini L, Lipsky BA, Madder J. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis. 2005;9(3):127-38.
Lew D, Waldvogel F. Osteomyelitis. Lancet. 2004;364(9431):369-79.
semisynthetic cephalosporin with
good in vitro activity
methicillin-susceptible staphylococci
nonenterococcal streptococci
Excellent tolerance
sex age
Cefazolin
resistancy pattern
18%
Male = 27
82%
Female = 6
Age Number %
0 – 14 yo 5 15
15 – 35 yo 21 64
36 – 55 yo 5 15
> 55 yo 2 6
Total 33 100
people
Hospitalization length Number %
0 – 10 days 4 peoples 12
25%
Cruris 13 px
39%
Femur 9 px
9% Humerus 3 px
Others 8 px
27%
Microorganism Operative specimen
Staphylococcus aureus 10
Staphylococcus haemoliticus 2
Pseudomonas aeruginosa 5
Alcaligenes faecalis 1
Burkholderia cepacia 2
Proteus mirabilis 2
Klebsiella pneumonia 2
Acinetobacter baumanii 1
Enterobacter aeruginosa 2
Morganella morganii 1
Staphylococcus epidermidis 3
Klebsiella terirgena 1
Prudencia stuartii 1
Total 33
16%
sensitif= 28
resisten =5
84%
Cefazolin used for >30 years to treat bone
and joint infections
Good activity against gram-positive cocci especially
methicillin-susceptible staphylococci
its excellent tolerance
its low cost
limited antimicrobial spectrum
Zeller V, Durand F, Kitzis D. Continuous Cefazolin Infusion To Treat Bone and Joint Infections: Clinical Efficacy, Feasibility, Safety, and Serum
and Bone Concentrations. Pub Med Central. 2009;53(3):883-7.
The most common pathogen microorganism is S aureus